Purpose of this Study
We are doing this study to see if the combination of an experimental drug called BGB-3245 (the study drug) and panitumumab is a safe and effective option for patients who have colorectal or pancreatic cancer with an RAS mutation.
Who Can Participate?
Eligibility
Adults ages 18+ who:
- Are diagnosed with advanced or metastatic RAS mutant colorectal cancer; OR
- Are diagnosed with RAS mutant pancreatic ductal cancer
For more information about who can join this study, please contact the study team at gi-oncology-cru@dm.duke.edu or 919-668-1861.
- Are diagnosed with advanced or metastatic RAS mutant colorectal cancer; OR
- Are diagnosed with RAS mutant pancreatic ductal cancer
For more information about who can join this study, please contact the study team at gi-oncology-cru@dm.duke.edu or 919-668-1861.
What is Involved?
If you choose to join this study, you will:
- Take the study drug in combination with panitumumab
- Have a tumor biopsy done, if necessary
- Have blood draws
- Have imaging scans (CT or MRI)
- Take the study drug in combination with panitumumab
- Have a tumor biopsy done, if necessary
- Have blood draws
- Have imaging scans (CT or MRI)
Study Details
Full Title
A Phase 1b, Open-Label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 with Panitumumab in
Patients with Advanced or Metastatic RAS mutant Colorectal and Pancreatic Ductal Cancers
Patients with Advanced or Metastatic RAS mutant Colorectal and Pancreatic Ductal Cancers
Principal Investigator
John
Strickler
Protocol Number
PRO00114943
NCT ID
NCT06194877
Phase
I
Enrollment Status
Open to Enrollment